GOLDEN, CO--(Marketwired - Feb 20, 2014) - iSatori, Inc. (OTCQB: IFIT), an emerging leader in the development and marketing of scientifically engineered nutritional supplements for healthier lifestyles, today announced a massive surge in demand for their already popular Meratrim® weight-loss product, Meratrim® Platinum+ (www.BioGeneticLabs.com), after the national airing of Meratrim® on the widely viewed Dr. Oz health show.
After the potential weight-loss benefits of this patented ingredient were discussed, in GNC, America's largest sports supplement retailer, where Meratrim® Platinum+ is currently the top-selling Meratrim-containing product, sales increased by 1132% in one week.
"iSatori first became interested in the science behind the Meratrim ingredient more than a year ago when we discovered two independent clinical research studies on the exclusive Meratrim® ingredient, which revealed very impressive weight-loss results, without the use of any stimulants," explains Stephen Adelé, Founder and Chief Executive Officer of iSatori, Inc. (www.isatori.com). Within the peer-reviewed scientific journals Obesity and Journal of Medicinal Food, they revealed significant weight loss in only two short weeks. "We knew this was the ideal type of scientifically validated ingredient to add to our popular weight-loss line of nutritional supplements, under our premium BioGenetic Laboratories brand. It was only a matter of time before the media would pick up on this impressive story, and we wanted to make sure our customers had access to it first, from us."
Two independent, randomized, double-blind, placebo-controlled studies -- the "gold standard" of clinical research -- on the Meratrim ingredient (a unique combination of the botanicals, Sphaeranthus indicus and Garcinia mangostana) were published recently in peer-reviewed scientific journals. The studies demonstrated combined results in 100 male and female participants of a significant reduction in weight, waist and hip circumference, and a host of reported health benefits as well as an increase in quality of life parameters compared to the placebo... all in as little as 14 days, and the study concluded up to eight weeks with equally impressive results. In addition to using Meratrim, study participants walked 30 minutes five days per week, and they followed a standard 2,000-kcal/day nutrition plan. It appears that each botanical plant contributes an essential part to Meratrim's ability to affect multiple pathways involved in fat cell formation and breakdown.
iSatori, under its BioGenetic Laboratories brand, is increasing production of Meratrim® Platinum+ in anticipation of the increasing media exposure and surging consumer demand. The product is available in GNC and Vitamin World stores nationwide and online at http://www.gnc.com/BioGenetic-Laboratories-Meratrim-Platinum-with-L-Carnitine-and-Green-Slimming-Tea-50-MORE-FREE/product.jsp?productId=23765826. As the exclusive distributor, Europa Sports, the nation's largest sports and health nutrition wholesale distributor, which supplies over 14,000 specialty and independent retailers, also carries Meratrim® Platinum+, along with the rest of the BioGenetic Laboratories products. Retailers interested in carrying Meratrim® Platinum+ can contact Europa Sports at 1-800-447-4795 or visit http://www.EuropaSports.com.
About iSatori, Inc.
iSatori is a consumer products firm that develops and sells nutritional products through online marketing, Fortune 500 retailers, and thousands of retail stores around the world. The Company is headquartered in Golden, Colorado, and its common stock trades on the OTCQB under the symbol "IFIT." More information about the Company is available at http://www.isatori.com. More information on Meratrim® Platinum+ can be found at http://www.biogeneticlabs.com/meratrimplatinum-Lcarnitine-green-slimming-tea.aspx
Statements made in this news release relating to the Company's future sales, expenses, revenue, product developments, and all other statements except statements of historical fact, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on assumptions and estimates that management believes are reasonable based on currently available information; however, management's assumptions and the Company's future performance are both subject to a wide range of business risks and uncertainties, and there is no assurance that these goals and projections can or will be met. Any number of factors could cause actual results to differ materially from those in the forward-looking statements, including, but not limited to, the timing and extent of changes in demand for the Company's products, the availability and price of ingredients necessary to manufacture such products, and the outcome of any current or future litigation regarding such products or similar products of competitors. All forward-looking statements are made only as of the date hereof, and the Company undertakes no obligation to update any such statement.